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Abstract 
Multiple sclerosis (MS) is a progressive inflammatory disease of the central nervous system 
(CNS) leading to severe neurological deficits. To date, no treatment is available that halts disease 
progression, but clinical symptoms can be generally improved by therapies involving anti-
inflammatory and/or immune modulatory reagents, which may cause off-target effects. Therefore, 
there remains a high and unmet need for more selective treatment strategies in MS. 
An early event in MS is a diminished function of the blood-brain barrier (BBB) which consist of 
specialized brain endothelial cells (BECs) that are supported in their barrier function by 
surrounding glial cells.   
Leakage and inflammation of the BECs in MS patients facilitate the massive influx of leukocytes 
into the brain parenchyma, which in turn induces irreversible demyelination, tissue damage and 
axonal dysfunction. Identification of ways to restore BBB function and promote its immune 
quiescence may therefore lead to the development of novel therapeutic regimes that not only 
specifically reduce leukocyte entry into the central nervous system but also restore the disturbed 
brain homeostasis. However, the complex network of molecular players that leads to BBB 
dysfunction in MS is yet to be fully elucidated. Recent discoveries unravelled a critical role for 
microRNAs (miRNAs) in controlling the function of the barrier endothelium in the brain. Here 
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we will review the current knowledge on the involvement of BBB dysfunction in MS and the 
central role that miRNAs play in maintaining BBB integrity under inflammatory conditions. 
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1. Multiple Sclerosis (MS), the disease and its characteristics 
1.1. MS: etiology and clinical course 
MS is a progressive disease of the central nervous system (CNS) with an autoimmune component. 
Predominant clinical symptoms include motor weakness, dysfunction or spasticity in about 50% 
of patients, followed by sensory problems and fatigue (40%). About 1.3 million people are 
currently diagnosed with MS worldwide but estimates are that the total global prevalence is about 
2.5 million patients with a male/female ratio of 0.5 (1). The prevalence of MS has a strong 
geographical pattern, with the highest incidence in Europe (80 per 100.000) and the lowest in 
Africa (0.3 per 100.000).  
Despite considerable research efforts, the underlying causal factors for MS remain largely 
unknown. The common perception is that MS arises from a combination of genetic and 
environmental causes. Recent studies have identified a number of risk genes predisposing to MS 
although the influence of these genes on this disease may be limited since the predictive value of 
such known risk factors does not exceed 1% (2). That genetic predisposition is not the only factor 
involved in developing MS is also illustrated by the observations that disease concordance is 
about 30% for monozygotic twins and that children of MS patients have a 2% chance of getting 
MS during their lifetime, much higher than the 0.3% background risk for developing MS in the 
general population (3). 
The clinical course of MS is highly variable and difficult to predict for diagnosed patients. MS 
can manifest itself in three distinct disease patterns. The most common form of MS, 
approximately 85% of cases at diagnosis, is relapsing-remitting MS (RR-MS), characterized by 
periods of sudden reduction of neurologic function, followed by partial or complete recovery 
(remission). Between attacks, patients are free of disease progression. The average age of onset of 
RR-MS is 29 years (1). Most patients eventually progress to the secondary progressive (SP-MS) 
phase in which the remission periods no longer occur (3). The transition to the more progressive 
course of disease occurs in about 50% of the patients within ten years after diagnosis and the 
percentage steadily increases with disease duration, up to about 80% of patients initially 
diagnosed with RR-MS. A smaller group of patients (about 10%) experience a continuous 
progression of clinical symptoms without remissions from the onset (primary progressive or PP-
MS).  
 4 
1.2. MS underlying pathology  
Under normal conditions, the influx of peripheral leukocytes into the brain parenchyma is 
restricted by a highly specialized barrier that consists of the endothelial cells (ECs) that line the 
inner parts of the cerebral microvasculature, the so-called blood-brain barrier (BBB). Therefore, 
the brain is often referred to as an immune privileged organ. However, this privilege is not 
absolute and immune surveillance by the adaptive immune system is a normal physiological 
process, especially close to the ventricles, choroid plexus, meninges and circumventricular organs 
(4;5). In recent years, it has become clear that, due to the specific immune status of the brain, the 
immune response in the brain may differ from that in peripheral tissues (6).  
In MS, lesion formation is a local phenomenon that occurs predominantly in the white matter of 
the CNS, mostly near the spinal cord, brain stem, optic nerve and periventricular areas (7). White 
matter (WM) lesions are inflammatory areas with a local dense infiltration of myelin-loaded 
(foamy appearing) macrophages accompanied by a variable amount of perivascular and 
parenchymal T lymphocytes. Usually few B cells are found in active lesions (8). Such lesions can 
be readily detected using magnetic resonance imaging (MRI), as failure of the BBB allows the 
ingress of vascular contrast agents at the lesion site. The infiltrating immune cells subsequently 
cause degradation of the myelin sheaths that line the axons, leading to diminished nerve signal 
propagation, axonal loss and ultimately severe disability of patients. Active, inflammatory lesions 
are a hallmark of RR-MS (9), while progressive forms of MS are less defined by acute 
inflammation. In progressive MS, chronic progressive neurodegeneration is the most prominent 
pathological feature, which results in diffuse white matter abnormalities and accumulation of 
axonal loss (10;11).  
However, the WM is not the only area  affected by the disease as lesions can be detected in the 
grey matter (GM) as well (12). GM lesions are characterized by activated microglia, 
demyelination and neurodegeneration, but infiltrating leukocytes are scarcely detected. BBB 
failure in GM lesions is less prominent, although subtle but persistent BBB malfunctioning has 
been demonstrated (13). Accumulating evidence suggests that GM atrophy plays an important 
role in MS pathogenesis and develops early in disease (14;15). Whether these different forms of 
neuroinflammation are connected or rather independently developing processes is still an active 
research topic. 
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1.3. The BBB in MS 
In MS, the BBB becomes diminished and loses its protective function both in the relapsing 
remitting and the progressive phases of the disease. Importantly, BBB dysfunction is considered 
a common denominator in several other neurological conditions such as Parkinson’s disease (PD), 
stroke and epilepsy. A dysfunctioning BBB may contribute to neurological problems that are 
associated with HIV infection (16) and possibly plays a role in Alzheimers Disease (AD) (17). 
This raises the question whether BBB failure is a mere consequence of these diverse pathologies 
or the underlying cause of observed neuropathologies (or both). The BBB is formed by 
microvascular brain endothelial cells (BMVECs) which are in close contact with surrounding 
pericytes, astrocytes, neurons and the extracellular matrix; together forming the so-called 
neurovascular unit (18). Cellular interactions induced by their close proximity are essential to 
maintain the unique BBB properties of BMVECs. 
In contrast to peripheral endothelium, the endothelial lining of the vessels in the brain is not 
fenestrated, but forms a closed polarized structure that enables selective nutrient uptake and 
waste product efflux (19). Adjacent ECs are sealed together by tight junction (TJ) proteins in 
order to limit paracellular influx of blood-borne cells, proteins or small molecules into the brain. 
Transport of nutrients into the brain parenchyma is closely regulated by specific transporters 
which provide the brain with essential glucose and amino acids. Efflux of waste or unwanted 
products from the brain is actively regulated by ATP-binding cassette (ABC) transporters (20) 
which are highly expressed on the luminal side of BMVECs. Numerous small molecules are 
substrates for ABC transporters and effluxed from the BMVECs, thereby protecting the brain 
from potential neurotoxic compounds.  
In active MS lesions large numbers of leukocytes migrate across the immune activated BBB. 
Transendothelial migration of leukocytes may occur via two pathways; paracellular, in which the 
leukocyte passes between adjacent endothelial cells or transcellular in which the leukocyte travels 
through the ECs, leaving the junctions intact (21). Leukocyte migration through the BBB is a 
complex process that is tightly regulated by the interplay of various cell adhesion molecules 
(CAM), integrins, cytokines and chemokines (22;23). In MS, leukocyte diapedesis most likely 
occurs at post capillary venules (21;24).  
By in vitro studies, it was shown that leukocyte diapedesis negatively influences BBB integrity 
thereby aggravating BBB failure (25). This observation is supported by studies using 
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Natalizumab or Alemtuzumab, recently established monoclonal antibody therapies for MS, which 
demonstrated that blocking T cell infiltration into the brain not only reduces the inflammation but 
also reduces the number of gadolinium-enhanced lesions dramatically (26). This suggests the 
involvement of the BBB early in the disease process. Indeed, in the established animal model for 
MS, experimental allergic encephalomyelitis (EAE), it was shown that BBB leakage precedes 
leukocyte influx (27;28).  
1.4. Available treatment 
Nowadays, the treatment of MS is aimed at relieving symptoms and reducing disease progression. 
Disease-modifying drugs (DMD) aim to reduce relapse frequency and accumulated disability in 
RR-MS. Because MS is considered to be an autoimmune disease, the majority of currently 
developed DMDs target the immune system. This approach is moderately effective in RR-MS but 
has little benefit for patients suffering from progressive forms of MS.  
The first line of treatment of MS is interferon (IFN)-β (Avonex, Rebif or CinnoVex). IFN-β 
delays the relapse frequency and shows a slight but significant effect on the accumulation of 
disability over three years (3). However, this drug has no beneficial effects in the progressive 
phase of the disease, either primary or secondary. Adverse effects of IFN-β are limited to flu-like 
reactions. Importantly, about 5-30% of the patients on IFN-β treatment develop neutralising 
antibodies, thereby reducing treatment efficacy. Another DMD is glatiramer acetate (Copaxone). 
It is a random polymer (of about 6.4 kDa) made from four amino acids that are present in myelin 
basic protein (MBP), a structural component of myelin. The exact mechanism of action for 
glatiramer remains unknown but treatment results in general dampening of the immune response 
(29). In a long-term study (15 years), it was shown that glatiramer treatment reduces the 
frequency of relapses in patients with RR-MS, but the number of patients that developed SP-MS 
was comparable to that of patients on placebo treatment (30).  
Mitoxantrone (Novantrone) was originally developed as an anti-cancer drug with its major 
mechanism of action the inhibition of DNA and RNA synthesis. In MS, treatment of patients 
with mitoxantrone leads to decreased differentiation of the T cell, B cell and macrophage cell 
pools, thereby acting as a general immunomodulatory therapy (31). Patients on mitoxantrone 
experience some beneficial effects, but at the risk of developing severe side effects such as a 
acute leukaemia and cumulative cardiotoxicity (32). Fingolimod (Gilenya) is a sphingosine -1 – 
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phosphate (S1P) receptor agonist which limits general leukocyte egress from lymph nodes, 
thereby reducing numbers levels of circulating leukocytes, limiting leukocyte entry into the CNS 
(33). Fingolimod reduces both relapse rate (by 54%) and progression to disability (by 30%) in 
MS patients compared to placebo (34). Teriflunomide (Aubagio) is a new oral anti-inflammatory 
drug that was approved for treatment of relapsing forms of MS in several regions including 
Europe, North America, Latin America and Australia (35-37). The active compound is the 
metabolite of leflunomide. Leflunomide was previously approved for the treatment of rheumatoid 
arthritis (38) and was shown to possess disease modifying properties in relapsing remitting MS. 
Although the therapeutic mode of action in MS is not fully understood yet, teriflunomide acts as 
an inhibitor of dihydroorotate-dehydrogenase (DHODH), an enzyme located in the mitochondria, 
which is involved in the biosynthesis of pyrimidines. This inhibition leads to a reduction of 
lymphocytes proliferation and function (39;40). Another new drug which is also used for the 
treatment of relapsing MS is Dimethyl fumarate (Tecfidera), also know as BG-12. It is a derivate 
of fumarate which has been used for decades in the therapy of psoriasis (41). Dimethyl fumarate 
and its main metabolite, monomethyl fumarate, act as modulators of nuclear factor E2-related 
factor-2 (NRF-2) pathway. This pathway directly regulates the response to oxidative stress and 
modulates immune response. Although the exact mechanism of action is not fully elucidated yet, 
dimethyl fumarate shows an inhibitor effect on immune cells as well as on the expression of 
adhesion molecules and proinflammatory cytokines. It also shows anti-oxidant properties (42). 
Natalizumab (Tysabri) is a monoclonal antibody against VLA-4 (α4β1 integrin), which is 
expressed on the surface of lymphocytes. It reduces the relapse rate at 1 year by 68% and the 
chance of acquiring permanent disability in a two year period by 42% (43). Unfortunately, about 
10% of the patients develop neutralising antibodies and in some cases (3.4 per 1000 patients) the 
use of Natalizumab can cause progressive multifocal leukoencephalopathy (PML), a viral 
infection of the brain which can be fatal (43). Whether Natalizumab is effective in SP-MS is now 
being assessed. 
Together, the data above indicate that suppressing the immune system is beneficial in reducing 
the number of relapses and, to some extent, in decreasing accumulated disability in MS. However, 
this therapeutic approach cannot halt disease progression, nor can it offer relief in progressive 
forms of MS. In addition, it may lead to serious side effects and, therefore, there remains a high 
and unmet need for the discovery of more specific drugs aimed at modulating MS disease 
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progression. As the BBB plays a prominent role in MS disease pathogenesis, preventing BBB 
failure or accelerating its recovery by restoring inflammation-induced molecular changes may 
well provide a novel way of modulating disease progression.  
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2. MicroRNAs (miRNAs) are key regulators of protein expression 
Although it has been generally assumed that most relevant genetic information is transmitted by 
proteins, during recent decades it has become clear that the majority of the genomes of mammals 
and other complex organisms is in fact transcribed into RNAs that do not encode for protein, so 
called non-coding RNAs (ncRNAs). The discovery of thousands of ncRNAs has been driven by 
large-scale genome sequencing, chromatin immunoprecipitation and genome tiling approaches 
(44;45). Until recently, most of the known ncRNAs (rRNAs, tRNAs and small nuclear and 
nucleolar RNAs) were implicated in relatively generic processes in a cell ultimately leading to 
the synthesis of protein. Recent evidence suggests that ncRNA plays an important role in cell 
biology and orchestrates many physiological and pathophysiological processes in mammalians 
(for review see (46-52)). In fact, while only 2% of the human genome encodes mRNA and leads 
to the synthesis of protein, the majority is described as long (>200 nt) and short (<200 nt) 
ncRNAs. So far, a diverse set of small regulatory RNAs have been identified and characterized 
including miRNAs, PIWI-interacting RNAs (piRNAs) and promoter associated RNAs (PASRs) 
and more recently miRNAs that can act as competitive endogenous RNAs (ceRNAs) (53). 
MiRNAs are small, about 22 nucleotides, endogenous ncRNA sequences. One of their most 
important functions is regulation of protein expression by sequence specific binding to the 3’ 
untranslated regions (3’UTRs) of target mRNAs, leading to altered protein expression. Although 
the first reports on functional short ncRNA sequences (later named miRNAs) in Caenorhabditis 
Elegans stem from the early 1990’s (54;55), the first reports linking miRNAs to disease status 
started emerging from 2006. Since then it was discovered that miRNAs are deregulated in 
numerous diseases and play a role in many cellular processes. Research on miRNAs as 
biomarkers, regulators and potential therapeutic targets is still increasing.  
The general importance of miRNAs in cellular functioning was demonstrated in experimental 
developmental studies in which DICER, a protein essential for miRNAs processing, was 
eliminated. Indeed, loss of miRNAs processing led to abnormalities in cellular differentiation and 
to embryonic lethality (56;57). To date, over 1800 unique human precursor miRNAs sequences 
resulting in over 2500 mature miRNAs are annotated in miRbase (58) and still more are being 
discovered, greatly aided by the rapid development of deep sequencing techniques (59). However, 
many of these sequences need further functional analysis to determine whether they meet the 
criteria for miRNAs as described by Ambros and colleagues in 2003 (60).  
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2.1. MiRNAs: biogenesis, degradation and mode of action 
MiRNA loci can be found in intergenic regions or in introns, situated alone or in miRNA clusters 
(61;62). They are transcribed by RNA polymerase II and III, processed by Drosha and Dicer and 
eventually loaded into the RNA-induced silencing complex (RISC) (62) (Figure 1). The miRNA 
guides the RISC complex to the target mRNA, where it binds to the 3’UTR region, leading to 
either destabilisation and degradation of the targeted mRNA or to repression of mRNA 
translation (63). Whether mRNA degradation or translation inhibition is the dominant mechanism 
of action is still an active topic of debate (64). Several papers show that significant protein down-
regulation is generally accompanied by reduced mRNA levels. The reduction of protein output is 
modest, up to 50%, leading to the notion that miRNAs are mostly involved in fine-tuning of 
protein expression levels (65;66). In line with this the recent discovery of miRNAs that has a 
function as ceRNAs is of high interest (53). 
Most mRNA 3’UTRs can bind several miRNA sequences and it has been shown that multiple 
different miRNAs can target one mRNA. The binding of one miRNA to its target is sufficient to 
downregulate protein expression significantly, which has been demonstrated in a large number of 
papers. However, binding of two different miRNAs to one mRNA enhances the repressing effect 
(67) and a combinational approach may be even more effective. The amount of microRNA that is 
available for mRNA regulation in the cell is governed by different mechanisms. Apart from the 
conventional binding of miRNA to mRNA targets, miRNAs can also bind to other RNA species 
such as circular RNA, long non-coding RNA or pseudogenes. These competitive endogenous 
RNAs (ceRNA) can bind microRNAs with microRNA response elements and indirectly de-
repress miRNA target mRNA (68). In other words, an increase in RNA can sponge up more 
miRNA, allowing other RNA to act unhindered. 
A number of recent studies show that miRNAs can also bind to their target mRNA outside the 
3’UTR sequence or to DNA sequences. Indeed, some miRNAs show effective simultaneous 3’ 
and 5’ UTR binding (69), or binding on mRNA sequences in the open reading frame (ORF) or on 
DNA promoter sites of a gene (69;70). In addition, miRNA binding to their target mRNA has 
been shown in certain cases to lead to mRNA stabilisation, resulting in protein up-regulation (71). 
Although these findings may open new avenues in the field of miRNA research, they are beyond 
the scope of this review and will not be discussed here in detail.  
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Current research is focussed on the biological effects of miRNAs either in health in specific cell 
types or tissues or during pathogenesis. Yet, relatively little is known about regulation of 
miRNAs expression by environmental stimuli. MiRNAs are located at diverse positions in the 
genome. They can be located in introns of protein-coding genes or in introns or exons of ncRNAs. 
Alternatively, miRNAs can be set between independent transcription units (intergenic) alone or in 
expression clusters (72). Even miRNAs located in introns have their own transcription regulatory 
pathways, as only one third of intronic miRNAs are transcribed simultaneously with their 
flanking gene (73). Thus, regulation of transcription is diverse and not governed by one single 
mechanism. Although miRNAs are generally considered to be stable RNA sequences, they have 
diverse half-lives in the cell (74). Some destabilising sequences have been identified, explaining 
more rapid breakdown for some sequences, but it was also shown that some mature miRNAs 
have different half-lives under different conditions such as cell cycle stage or stimulation with 
growth factors that can directly influence miRNA degradation. Several miRNases are known and 
these findings suggest that miRNAs levels are actively regulated.  
2.2. Identification of downstream targets of miRNAs 
Although there is a fair grasp on the mechanisms of action of some miRNAs, identifying direct 
targets of miRNAs has proven to be difficult. MiRNAs target prediction databases have been 
valuable in determining downstream targets, although the predictive value is limited. A recent 
study comparing different algorithms showed that the average precision of nine different 
programs was 17,3 % (67). Some programs get higher percentages of accurate predictions but 
they are significantly less sensitive; they fail to predict a large number of miRNA sequences that 
were found active.  
There are several ways of identifying physiological miRNAs targets, nicely reviewed by 
Thomson and colleagues (75). Most of them rely on over-expression or inhibition of a target 
miRNA in a cell line followed by assessing the downstream effects, for example, by 
transcriptome analysis or by assessing a specific cellular function. An unbiased approach for 
defining several targets on the protein level can be obtained by using proteomics after miRNAs 
up- or down-regulation. This is a successful approach, although some caution should be taken as 
indirect effects are hard to predict (e.g. a miRNA targeting a transcription factor), miRNA 
expression levels may vary during the cell cycle (76), and over-expression of miRNAs to non-
physiological levels may lead to non physiological effects (77). Once putative mRNA targets 
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have been identified for a miRNA, luciferase assays are commonly used in order to validate this 
prediction. The 3’-UTR sequence of the target gene is subsequently coupled to the luciferase 
gene, allowing luminescent readout of miRNA effects. Ideally, additional studies with mutations 
in the miRNA binding sequences are performed to confirm miRNA involvement, as there are 
other factors capable of binding at the 3’-UTR as well (78). 
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3. MiRNAs in MS 
MiRNAs can be released into the circulation by activated cells during the pathogenesis of a 
particular disease. Some of the circulating miRNA are located within exosomes and therefore 
they are protected from RNase digestion and degradation (79;80). Circulating miRNAs can also 
be protected from degradation through their association with specific proteins in order to form a 
protein-miRNA complex such as RISC or Argonaut proteins (81). While MS-associated changes 
in levels of miRNAs in many different cell type, including peripheral blood mononuclear cells 
(PBMCs) (82;83), B lymphocytes, CD4+,CD8+ T cell (68), peripheral blood leukocytes (83;84), 
and brain astrocytes (87) have already been proven, their functions in these cell types remains to 
be largely understood whereas the role of circulating miRNAs in MS progression has not yet 
been addressed.  
3.1. Circulating miRNAs in MS 
A recent study showed that in MS a specific circulating miRNAs signature can be recognized 
(88). ). Six specific miRNAs, miR-614, miR-648, miR-572, miR-422a, miR-1826 and miR-22 
were found to be significantly increased in the plasma of MS patients when compared to healthy 
controls (HC). Importantly, all but one of these miRNAs had not yet been associated with the 
pathogenesis of MS. Amongst the identified miRNA signature, miR-614 showed the highest fold 
change between MS patients and HC. This specific miRNA can regulates the expression of a 
Forkhead transcription factor, FOXD1, which can regulate inflammatory response by suppressing 
the activation of naïve T cell (89;90). Thus, high levels of miR-614 may lead to T cell 
proliferation and systemic inflammation (89). 
Another novel MS associated miRNA with highly expressed plasma levels in patients compared 
to control samples was miR-648. A predicted target of this miRNA is the MBP, a CNS-specific 
myelin protein, which is involved in the stabilization of the myelin sheath in the CNS (91). Once 
again, over-expression of this miRNA results in a reduction of MBP expression, thereby reducing 
myelin sheath stability. Furthermore, the expression profile of circulating miRNAs has shown to 
be different in RR-MS and SP-MS patients compared to HC and in RR-MS versus SP-MS, 
indicating a specific circulating miRNAs profile linked to disease stage and disability can be 
recognized (92). These studies together provide evidence of a unique circulating miRNAs 
signature in MS. Their role in disease pathogenesis remains to be established. However, the 
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identification of a specific panel of plasma derived miRNAs in different stages of the disease has 
laid the foundations for further analysis to use miRNAs as a promising biomarker for MS, which 
is highly sought for.  
3.2. MiRNAs as biomarker in MS 
The establishment of proper markers used to monitor a disease’s progression is an essential point 
for most pathological conditions including cancers, neurodegenerative disease, heart disease and 
diabetes. Circulating miRNAs possess the characteristics of promising biomarkers, especially 
since most are known to be stable in the circulation and resistant to RNase digestion and multiple 
freeze-thaw cycles (79). Moreover, the capability of miRNAs to act as gene regulators, make 
them potential more suitable as early stage disease biomarkers than proteins and genes.  
So far, several circulating miRNAs in plasma have been successfully identified as biomarkers for 
a number of diseases (93;94). For instance, specific glioma associated miRNAs were identified in 
serum-derived exosomes from patients affected by glioblastoma. This finding suggests that 
specific miRNAs released by tumor cells may be useful for diagnostic purpose (95). Additionally, 
the discovery of miRNAs in human salivary samples suggests a promising use of salivary 
exosomes as novel and easily accessible biomarkers for disease diagnosis (96).  
The function of exosomes as molecular carriers and their ability to delivery miRNAs to cells at a 
distance, ergo modify target cells gene expression, may further allow their use as diagnostic 
markers. This evidence allows us to postulate that miRNAs, especially those carried in the blood 
by exosomes, can be considered as ideal candidates for disease biomarkers. Furthermore, because 
exosome isolation is a non-invasive procedure and the subsequent characterization of the 
miRNAs expression profile is nowadays relatively straightforward, exosome profiling represent a 
great promise as a new diagnostic strategy. Further identification and characterization of 
exosomal and circulating miRNAs is pivotal in order to establish new miRNAs as biomarkers for 
diagnostic purposes and, therefore, potentially provide new insights into therapeutic strategies.  
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4. MiRNAs expression profiles in vascular beds in disease state 
The expression profile of miRNAs varies in different tissues, but few miRNAs were found 
exclusively expressed in specific cell types or tissues (97). In the following section, the effects of 
miRNAs and their regulation in different vascular beds will be discussed. 
4.1. Differential miRNAs expression in ECs 
ECs may have different characteristics depending on the surrounding tissue and it is therefore not 
surprising that the miRNA profile can differ as well. This is illustrated by McCall et al. (98) in a 
study comparing miRNA expression levels in healthy untreated human endothelial cells isolated 
from aorta (HAEC), coronary artery (HCEC), umbilical vein (HUVEC), pulmonary artery 
(HPAEC), pulmonary microvasculature (HPMVEC), dermal microvasculature (HDMVEC) and 
brain microvasculature (HBMVEC), the cells that form the BBB. In this study, 843 miRNAs 
were measured and 164 could be detected in ECs. Of these, 40% were differentially expressed in 
at least one comparison (e.g. HPAEC vs HCEC). Of note, the miRNA profile of HBMVEC 
showed the closest correlation with that of HUVEC cells instead of the other microvasculature 
lines. Three miRNAs were significantly different across all EC-types; let-7b, miR-20b and miR-
99b.  However, whether these three miRNAs (or others) contribute to maintaining the EC 
phenotype remains to be established.  
4.2. The role of miRNAs in endothelial function 
Vascular endothelial cells have many functions such as control of angiogenesis, response to 
inflammation and the regulation of blood coagulation (99). MiRNAs are known to be involved in 
all of these processes. Upon inflammatory stimuli induced by pro-inflammatory mediators such 
as cytokines or free radicals, numerous signalling pathways are activated in ECs. A central 
pathway in endothelial inflammation is NF-κB signalling, which results in the expression of 
multiple inflammatory genes such as adhesion molecules (P- and E-selectin, vascular cell 
adhesion molecule (VCAM) , intercellular adhesion molecule (ICAM)) and various cytokines 
and chemokines (100;101). Many miRNAs that are involved in endothelial inflammation target 
genes in this pathway (table 1). 
 An important driver of angiogenesis and endothelial permeability is the vascular endothelial 
growth factor (VEGF). It has been demonstrated in several studies that VEGF reduces barrier 
 16 
integrity by signalling through its receptors (102;103). Elevated VEGF levels were found in AD, 
PD and stroke; all conditions in which the BBB is compromised. It is known that VEGF 
signalling in ECs is directly influenced by multiple miRNAs among which miR-155 and miR-
126 (104). In an attempt to identify miRNAs which regulate the BBB, we recently performed 
expression analyses in an immortalized human cerebral microvascular endothelial cell 
(hCMEC/D3) line, hCMEC/D3 cells cultured under barrier-promoting or barrier-disturbing 
conditions. Using in vitro BBB models, we assessed miRNAs expression in hCMEC/D3 that 
were treated either with pro-inflammatory cytokines or astrocytes conditioned medium (ACM). 
Pro-inflammatory cytokines reduce barrier functioning, whereas ACM is capable of increasing 
barrier resistance. We found that under the barrier improving conditions, induced by ACM, many 
miRNAs were up-regulated. Conversely, treatment that results in lowered barrier resistance, i.e. 
pro-inflammatory cytokines, is accompanied by decreased miRNA expression levels. In short, we 
identified a set of microRNAs that are involved in BBB regulation. Within the miRNAs 
signatures, 50 miRNAs were identified that were regulated by both treatments, i.e. these miRNAs 
were downregulated in a leaky barrier and upregulated in a tight barrier. In a final set of 
experiments we wanted to show the relevance of such miRNAs in MS. To this end, we compared 
the expression of sixteen miRNAs in this specific set in BBB endothelial cells isolated from post-
mortem MS lesion areas compared to cells isolated from normal appearing white matter. 
Strikingly, all selected miRNAs were reduced in the BBB associated with MS lesions. Since 
subsequent studies showed that forced expression of miRNAs resulted in an increase in BBB 
function and reduced transendothelial migration of primary monocytes, a hallmark immune cell 
of MS, our results strongly indicate that therapeutic application of miRNAs could be a viable 
approach for treating diseases of the CNS which are marked by vascular dysfunction, in 
particular MS (105). In addition, this highly-specific MS miRNA signature can potentially be 
used as a biomarker for diagnosis, prognosis and treatment efficacy monitoring. 
4.3. MiRNAs in BBB functioning 
A small number of papers describe miRNAs in BBB functioning in various conditions. Mir-29a 
is reported to indirectly influence barrier functioning by targeting gene that regulate epigenic 
events (DNMT genes) and may be a contributing factor in ischemic brain injury (106). In another 
condition affecting BBB functioning, HIV infection, it was demonstrated that miR-101 
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expression is increased by the HIV Tat C protein. Mir-101 in turn directly targets VE-Cadherin 
expression and thus negatively influences barrier functioning (107). 
 MiR-155 is an extensively studied miRNA which has functions in inflammation (108), 
autoimmunity and proliferation (109). It is one of the most highly upregulated miRNAs in acute 
MS lesions (110). It was found that miR-155 is rapidly up-regulated under inflammatory 
conditions in vitro, has high expression levels in BECs, in the mouse EAE model and miR-155 
knockout mice develop less clinical symptoms. MiR-155 exerts its effects by directly targeting 
DOCK-1, SDCBP, ANXA-2 and Claudin-1 (111), all factors directly relevant to BBB 
functioning.  
Another relevant BBB miRNA is miR-125a-5p. miR-125a-5p is known as a tumour suppressor 
miRNA (112;113). It also has an anti-inflammatory function in macrophages by inducing the 
formation of anti-inflammatory type 2 macrophages (114). Moreover, we found that miR 125a-5p 
is severely reduced in endothelial cells derived from MS lesions and upon inflammatory stimuli 
in vitro. It directly regulated barrier function in an in vitro BBB model and can reduce monocyte 
migration through a BBB cell layer in vitro (105).  
Future research will be directed on the identification of specific miRNAs profiles that regulate 
BBB function under different pathological conditions, in order to come to a panel of miRNAs 
that may be suitable as therapeutic strategies to restore BBB function to prevent disease 
progression in MS. 
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5. Concluding remarks 
MiRNAs are important regulators of protein expression which are involved in many cellular 
processes. They may prove to be valuable diagnostic markers for a number of diseases and play a 
yet enigmatic role in intercellular communication. In neuroinflammation, a clear role for 
miRNAs is emerging as key regulators of endothelial functioning and endothelial response to 
external stimuli. We and others have shown that miRNA expression levels are altered under 
inflammatory conditions as seen in MS and potentially several other neurological conditions. 
Moreover, there are clear indications that restoring miRNA expression levels is beneficial for 
BBB functioning.   
The potential of miRNAs as therapeutic agents is, at this point in time, still rather limited. There 
are some clear advantages for targeting miR sequences as a therapeutic approach. MiRNAs have 
several predefined targets which will all be influenced by the same sequence. Therefore miRNAs 
are regulators of cellular functions by targeting several key genes in a pathway rather than by a 
single target approach, such as siRNA. The sequence is endogenous and is therefore not likely to 
elicit immune responses. Moreover, the exact nucleotide sequence of the targeted miRNA is 
known, limiting lead optimisation to chemical stabilisation and optimisation of delivery. 
Despite the relative novelty of the field, two miRNA-based strategies are currently being tested in 
clinical trials, paving the way for further development of miRNA-based therapeutics. One such a 
therapy involves Miravirsen, a miR-122 inhibitor used for treating hepatitis C, which showed 
efficacy in a phase II clinical trial (115). Recently, Mirna Therapeutics started a clinical phase I 
trial using a miR34a mimic for unresectable primary liver cancer. Based on the outcome of such 
studies, the use of miRNA-based therapeutic approaches to restore BBB function in MS may 
become within reach.  
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6. Abbreviations 
MS: Multiple sclerosis  
CNS: Central nervous system 
BBB: Blood-brain barrier 
BECs: Brain endothelial cells 
miRNA: microRNA 
RR-MS: Relapsing-remitting MS 
SP-MS: Secondary progressive MS 
PP-MS: Primary progressive MS 
ECs: Endothelial cells 
GM: Grey matter 
BMVECs: Microvascular brain endothelial cells 
CAM: Cell adhesion molecules 
DMD: Disease-modifying drugs 
INF-β: Interferon beta 
MBP: Myelin basic protein 
ncRNAs: Non-coding RNAs 
ceRNAs: Competitive endogenous RNAs 
UTR: Untranslated region 
RISC: RNA-induced silencing complex 
HC: Healthy controls 
VEGF: Vascular endothelial growth factor 
hCMEC/D3: Human cerebral microvascular endothelial cell  
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Figure 1: miRNA biogenesis.  
MiRNAs are transcribed from the genome (sometimes in clusters as depicted) by RNA 
polymerase resulting in the pri-miRNA. Drosha processes the pri-miRNA to a pre-miRNA which 
is a 70-100 nt hairpin structure. The pre-miRNA is exported to the cytoplasm by exportin-5 and 
cleaved by dicer, resulting in an active and a passenger strand. The passenger strand is degraded 
and the active strand is loaded into the RISC complex. The miRNA guides the RISC complex to 
the target mRNA leading to translational repression or mRNA degradation   
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 Table 1: MiRNAs with endothelial functions 
MicroRNA Process Molecular Targets Reference 
Hsa-miR-361-5p Angiogenesis VEGF (116) 
Hsa-miR-124 Angiogenesis Ras (117) 
Hsa-miR-125b Angiogenesis MAZ (118) 
Hsa-miR-146 Angiogenesis/Inflammation IRAK1, TRAF6, HuR, TLR4 (119) 
Has-miR-126 Angiogenesis/Inflammation VCAM, VEGFR2 (120;121) 
Hsa-miR-155 Angiogenesis/Inflammation VEGFR2/ANXA2, CLDN1, 
SDCBP, DOCK1 
(101;111) 
Hsa-miR-125a-5p Angiogenesis/Inflammation Endothelin-1/ TJ proteins (105;122) 
Hsa-miR-138 Inflammation S110A1 (123) 
Hsa-miR-712 Inflammation TIMP-3 (124) 
Hsa-miR-149 Inflammation ?, TNF pathway (125) 
Hsa-miR-181 Inflammation Importin α3 (100) 
Hsa-miR-221 Inflammation Ets-1 (126) 
Hsa-miR-31 Inflammation E-selectin (127) 
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